J&J just sped(#before 2020-03-31 16:07:59) up the timeline for its coronavirus vaccine, and said(#included early next year) the timeline for its coronavirus vaccine, could be ready for emergency(#included early next year) use early next year .
2020-03-31 16:07:59 +00:00 .
Associated Press
J&J is accelerating(#overlap 2020-03-31 16:07:59) the timeline for its coronavirus vaccine, , saying(#included Monday) a coronavirus vaccine could be available for emergency(#included early next year) use by early next year .
Johnson Johnson said(#included Monday) Monday J&J has selected(#included Monday) a lead vaccine candidate and plans(#before 2020-03-31 16:07:59) to start(#included early next year) testing(#included early next year) a lead vaccine candidate in people no later than September .
J&J also pledged(#before 2020-03-31 16:07:59) J&J will ramp up manufacturing(#before 2020-03-31 16:07:59) to supply(#after 2020-03-31 16:07:59) 1 billion doses of a vaccine to The world 's .
a coronavirus vaccine would be affordable to the public " on a not - for - profit basis for emergency(#before 2020-03-31 16:07:59) pandemic(#before 2020-03-31 16:07:59) use , " J&J stated(#before 2020-03-31 16:07:59) .
Previously , J&J said(#before 2020-03-31 16:07:59) J&J was aiming(#included November) to start(#included November) clinical trials(#included November) in November .
Visit Business Insider 's homepage for more stories .
Johnson Johnson announced(#included Monday) Monday an accelerated(#included Monday) timeline that could lead(#after 2020-03-31 16:07:59) to a coronavirus vaccine that 's ready for emergency use in early 2021 .
J&J said(#before 2020-03-31 16:07:59) J&J has identified(#before 2020-03-31 16:07:59) a lead vaccine candidate to bring(#before 2020-03-31 16:07:59) into human testing .
Testing(#included September 2020) should begin(#included the fall) by the fall and produce(#included September 2020) clinical results on safety and efficacy by the end of 2020 , J&J said(#before 2020-03-31 16:07:59) .
" J&J are moving(#included November) on an accelerated(#after 2020-03-31 16:07:59) timeline toward Phase 1 human clinical trials(#included September 2020) at the latest by September 2020 and , supported(#included September 2020) by the global production(#included September 2020) capability that J&J are scaling(#included November) up in parallel to human testing , J&J expect(#included early 2021) a vaccine could be ready(#included early 2021) for emergency use in early 2021 , " said(#before 2020-03-31 16:07:59) Paul Stoffels , J&J chief scientific officer , in a statement .
Read more :
There are more than 40 potential coronavirus vaccines in the works .
Here are the top efforts to watch(#included November) , including(#included November) the 8 vaccines set(#included 2020) to be tested(#included 2020) in people this year .
J&J also pledged(#before 2020-03-31 16:07:59) to make(#overlap 2020-03-31 16:07:59) a vaccine affordable to the public , adding(#before 2020-03-31 16:07:59) J&J would distribute(#after 2020-03-31 16:07:59) a vaccine on a " not - for - profit basis for emergency(#before 2020-03-31 16:07:59) pandemic(#before 2020-03-31 16:07:59) use .
"
J&J said(#before 2020-03-31 16:07:59) J&J will ramp up manufacturing(#before 2020-03-31 16:07:59) to be able to supply(#after 2020-03-31 16:07:59) at least 1 billion doses of a vaccine to The world 's .
J&J has been researching(#after 2020-01) the genetic sequence of a coronavirus vaccine that 's ready for emergency use in early 2021 since January in partnership with Beth Israel Deaconess Medical Center .
After producing(#before 2020-03-31 16:07:59) several vaccines , several vaccines were tested(#before 2020-03-31 16:07:59) to identify(#before 2020-03-31 16:07:59) the most promising ones at causing(#before 2020-03-31 16:07:59) an immune response(#before 2020-03-31 16:07:59) .
The vaccine 's development is also being supported(#before 2020-03-31 16:07:59) by the Biomedical Advanced Research and Development Authority ( BARDA ) .
J&J and the Biomedical Advanced Research and Development Authority ( BARDA ) have committed(#before 2020-03-31 16:07:59) more than $ 1 billion to The vaccine 's development , J&J stated(#before 2020-03-31 16:07:59) .
The update(#included November) shortens(#included November) an already quick timeline for vaccine development(#after 2020-03-31 16:07:59) , Previously , J&J said(#before 2020-03-31 16:07:59) J&J was aiming(#included November) to start(#included November) testing(#included November) a coronavirus vaccine in humans in November .
Vaccine development typically takes(#before 2020-03-31 16:07:59) five to seven years before applying(#before 2020-03-31 16:07:59) for regulatory approval(#before 2020-03-31 16:07:59) , J&J stated(#before 2020-03-31 16:07:59) .
In this case , J&J is expecting(#included November) it to take(#after 2020-03-31 16:07:59) about a year to go(#after 2020-03-31 16:07:59) from early research(#before 2020-03-31 16:07:59) to emergency(#before 2020-03-31 16:07:59) approval(#after 2020-03-31 16:07:59) , if needed(#Depend-on 2020-03-31 16:07:59) .
There are more than 40 ongoing research programs(#overlap 2020-03-31 16:07:59) for a coronavirus vaccine .
All are attempting(#overlap 2020-03-31 16:07:59) to speed(#after 2020-03-31 16:07:59) up the lengthy development process to halt(#after 2020-03-31 16:07:59) a coronavirus vaccine , and the speediest efforts have already started(#before 2020-03-31 16:07:59) to be tested(#before 2020-03-31 16:07:59) in humans in record time .
Read more : ' Crazy hours , short nights ' : The inside story of how a buzzy biotech upstart developed(#before 2020-03-31 16:07:59) a potential coronavirus vaccine in record time US health officials , including(#before 2020-03-31 16:07:59) The world 's top infectious disease expert Anthony Fauci , have repeatedly stated(#before 2020-03-31 16:07:59) it will take(#after 2020-03-31 16:07:59) at least a year to know if any vaccine is safe and effective against a coronavirus vaccine that 's ready for emergency use in early 2021 .
Read the original article on Business Insider 's
